Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$29.35 USD

29.35
3,320,301

+0.85 (2.98%)

Updated Oct 16, 2024 04:00 PM ET

After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost

Achillion Pharmaceuticals' (ACHN) fourth-quarter loss wider than estimates. The company is focusing on operational restructuring to save costs.

    Corcept's (CORT) Earnings and Sales Meet Estimates in Q4

    Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.

      Medicines Company (MDCO) Reports Q4 Loss, Revenues Slump Y/Y

      Medicines Company (MDCO) incurs wider-than-expected loss in the fourth quarter of 2017. Moreover, the top line declines year over year on low Angiomax sales.

        Will Mylan (MYL) Disappoint Investors This Earnings Season?

        During the Q4 earnings call, investors are expected to remain focused on the performance of Mylan's (MYL) EpiPen, newly launched drugs and the progress of the biosimilars pipeline.

          Will Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again?

          Exelixis (EXEL) is likely to beat on earnings in the fourth quarter (results due on Feb 26) driven by growth in Cabometyx sales.

            What's in Store for Agenus (AGEN) This Earnings Season?

            Agenus (AGEN) is expected to provide updates on pipeline candidates when it reports Q4 numbers on Mar 8.

              Key Factors to Influence Penumbra's (PEN) Earnings in Q4

              Penumbra (PEN) expects to gain from solid performance by neuro and peripheral vascular arms in Q4. Strong growth across all geographies is likely to drive the top line.

                What's in Store for Veeva Systems (VEEV) in Q4 Earnings?

                Consistent focus on Subscription Services is likely to drive Veeva Systems (VEEV) in Q4.

                  Is a Beat in Store for Inogen (INGN) This Earnings Season?

                  Strong product portfolio and a unique direct-to-consumer business model are expected to drive Inogen (INGN) in Q4.

                    Will ACADIA (ACAD) Disappoint Investors in Q4 Earnings?

                    ACADIA (ACAD) is expected to provide further update on the progress of Nuplazid when it reports Q4 results on Feb 27.

                      What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?

                      Although Juno Therapeutics' (JUNO) product portfolio lacks revenue figures, the company's most advanced pipeline candidates, JCAR017 and JCAR014, might still drive the stock in Q4.

                        Can PBM Unit Drive Express Scripts' (ESRX) Earnings in Q4?

                        Express Scripts (ESRX) expects Q4 results to show earnings growth on strength in PBM segment.

                          What to Expect From BioMarin (BMRN) This Earnings Season?

                          BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q4. On the call, management is likely to comment on Brineura's launch progress and on the launch preparation for pegvaliase.

                            What's in the Cards for Geron (GERN) This Earnings Season?

                            With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.

                              Novartis Psoriasis Drug Cosentyx Positive in SCALP Study

                              Novartis (NVS) announces positive results from the phase III study on multi-blockbuster drug Cosentyx for the treatment of moderate-to-severe scalp psoriasis.

                                What's in Store for Ligand (LGND) This Earnings Season?

                                Ligand's (LGND) Captisol formulation technology aids the company to form partnerships with several leading healthcare companies. This in turn might drive the stock in Q4.

                                  AbbVie Presents New Data on Upadacitinib for Crohn's Disease

                                  AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.

                                    Celgene Reports Positive Data on Dermatology Drug Otezla

                                    Celgene (CELG) is looking to expand dermatology drug Otezla's label and reported positive data from a late-stage study in patients with active Beh??et???s Disease.

                                      Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat

                                      Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.

                                        Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion

                                        Roche (RHHBY) announces that it will acquire Flatiron Health to accelerate development and delivery of breakthrough drugs for cancer patients.

                                          Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates

                                          Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.

                                            Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View

                                            Zoetis' (ZTS) results exceed both earnings and sales expectations in the fourth quarter of 2017, making it the first animal health company to deliver more than $5 billion in revenues.

                                              Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y

                                              Agios (AGIO) reports wider-than-expected loss in the fourth quarter of 2017. Revenues fall short of expectations. The top line also declines year over year.

                                                Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses

                                                Prothena (PRTA) reported a narrower-than-expected loss in the fourth quarter as the company continued with its pipeline progress.

                                                  Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong

                                                  Shire (SHPG) reported better-than-expected fourth-quarter earnings and also registered strong growth in immunology franchise and newly launched products.